Also known as: J&J
Johnson & Johnson is a global healthcare company focused on innovative medicine and medtech. The company says it has been helping people stay well at every age and stage of life since 1886 and operates across the full spectrum of healthcare solutions.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
A study in JAMA Open finds that anti-kickback penalties paid by pharma companies amounted to just 2.2% of U.S. revenue from involved drugs. Pfizer recently disclosed $60,000 in lobbying on drug pricing and vaccine issues. Researchers say settlements act as a cost of doing business.
Johnson & Johnson is preparing a potential sale of its DePuy Synthes orthopedics unit, valued at over $20 billion, with private equity firms showing interest. Concurrently, the unit has acquired spine implant maker Expanding Innovations to bolster its technology portfolio.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07740486 |
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07738887 |
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07696975 |
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF |
NOT_YET_RECRUITING | NA |
| NCT07655479 |
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support |
RECRUITING | |
| NCT07649525 |
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level |
RECRUITING | PHASE3 |
| NCT07638683 |
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). |
RECRUITING | PHASE2 |
| NCT07551856 |
Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07534462 |
Echocardiographic Assessment of the Effect of Impella on Biventricular Function |
NOT_YET_RECRUITING | |
| NCT07532473 |
REal World MAIA UK OutcomEs |
NOT_YET_RECRUITING | |
| NCT07507409 |
Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients |
NOT_YET_RECRUITING | PHASE4 |
